Patient-Reported Outcomes From Males Regarding Germline Testing for Prostate Cancer: Results From the PROGRESS Registry
JCO Precision Oncology · 2025
DOI: 10.1200/po-25-00571 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Precision Oncology, 2025. Verfasst von Stacy Loeb und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology and Population Health, New York University Langone Health and Manhattan Veterans Affairs, New York, NY. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Genetic Testing, Patient Reported Outcome Measures. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE Prostate cancer (PCA) germline testing (GT) informs precision therapy, cancer screening, and hereditary cancer risk for patients and families. To support patient-centered PCA GT, studying patient-reported outcomes (PROs) is essential. METHODS PROGRESS was a national patient-driven registry (January 2021-April 2022) for English-speaking males older than 18 years with previous/current PCA GT and Internet access. Surveys collected demographics, PCA history, family cancer history, mode of genetics care delivery, satisfaction with genetic counseling, decisional conflict, cancer genetics knowledge, and attitudes toward GT. Multiple linear regression modeling was used to estimate and draw inferences (α = .05) on strength of relationships between participant characteristics and PROs. RESULTS Analyses focused on 414 participants: White (88%), Black (3%), Asian (6%), and mixed/other (3%). Most participants were non-Hispanic (95.2%) and 46.9% had PCA. Genetic results were positive (pathogenic/likely pathogenic variants; mutations) in 27.9%. The three most common modes of genetics care were meeting with genetics professional (in-person or remotely; 30.9%), discussing with doctor (21.1%), and using website (20.8%). In covariate-adjusted models, satisfaction scores were highest with pretest counseling by phone (β = 1.31; 95% CI, 0.26 to 2.36) or discussion with doctor (β = 1.25; 95% CI, 0.38 to 2.12). Lower decisional conflict scores were reported for pretest counseling by phone (β = −3.76; 95% CI, −7.28 to −0.24). Males with mutations reported higher GT benefit scores (β = .30; 95% CI, 0.02 to 0.59) and importance of GT (β = .34; 95% CI, 0.08 to 0.61). Asian Americans reported lower GT satisfaction (β = −2.91; 95% CI, −4.34 to −1.48) and higher decisional conflict (β = 8.93; 95% CI, 4.36 to 13.51). CONCLUSION PROGRESS Registry informs the first comprehensive report of PROs among males undergoing PCA GT, providing insights into opportunities to improve patient experience and leverage the benefit of GT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Urology and Population Health, New York University Langone Health and Manhattan Veterans Affairs, New York, NY.
- Division of Biostatistics and Bioinformatics, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA.
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, Philadelphia, PA.
- Section of Medical Oncology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT.
- OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, OR.
- Exact Sciences Corporation, Madison, WI.
ORCID-Profile: Stacy Loeb, Scott W Keith, Rebecca L Hartman, Tomasz M Beer, Karina L Brierley, Heather H Cheng, Adam P Dicker, Lawrence Karsh, William K Kelly, Amy E Leader, Patrick Mille, Channing J Paller, Huma Q Rana, Alexandra O Sokolova, Edouard J Trabulsi, Young E Whang, Veda N Giri
Förderung
- NCI NIH HHS
Zitieren
APA
Loeb, S., Keith, S. W., Gross, L., Hartman, R. L., Beer, T. M., Brierley, K. L., Cheng, H. H., Couvillon, A., Dicker, A. P., Friedman, S., Gomella, L. G., Karsh, L., Kelly, W. K., Lallas, C. D., Leader, A. E., Mann, M. J., Mark, J. R., Mille, P., Paller, C. J., …, & Giri, V. N. (2025). Patient-Reported Outcomes From Males Regarding Germline Testing for Prostate Cancer: Results From the PROGRESS Registry. JCO Precision Oncology. https://doi.org/10.1200/po-25-00571
Vancouver
Loeb S, Keith SW, Gross L, Hartman RL, Beer TM, Brierley KL, et al. Patient-Reported Outcomes From Males Regarding Germline Testing for Prostate Cancer: Results From the PROGRESS Registry. JCO Precision Oncology. 2025. doi:10.1200/po-25-00571
BibTeX
@article{Loeb2025,
author = {Loeb, Stacy and Keith, Scott W and Gross, Laura and Hartman, Rebecca L and Beer, Tomasz M and Brierley, Karina L and Cheng, Heather H and Couvillon, Anna and Dicker, Adam P and Friedman, Sue and Gomella, Leonard G and Karsh, Lawrence and Kelly, William K and Lallas, Costas D and Leader, Amy E and Mann, Mark J and Mark, James Ryan and Mille, Patrick and Paller, Channing J and Rana, Huma Q and Sokolova, Alexandra O and Trabulsi, Edouard J and Whang, Young E and Giri, Veda N},
title = {Patient-Reported Outcomes From Males Regarding Germline Testing for Prostate Cancer: Results From the PROGRESS Registry},
journal = {JCO Precision Oncology},
year = {2025},
doi = {10.1200/po-25-00571}
}
EUVIMED